r-18

Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.

R18 TFA, a peptide antagonist of 14-3-3, exhibits a dissociation constant (K_D) of 70-90 nM. It efficiently inhibits the interaction between 14-3-3 and its physiological ligand, the kinase Raf-1, thereby significantly impeding the protective effect of 14-3-3 on Raf-1 against phosphatase-induced deactivation [1].

OR-1896 is the active metabolite of Levosimendan, a highly specific phosphodiesterase (PDE III) inhibitor, a vasodilator with partial anti-inflammatory properties that produces vasodilation in different types of blood vessels through activation of ATP-sensitive (KATP) and other potassium channels.OR-1896 can be used to study heart failure and vascular dysfunction. OR-1896 can be used to study heart failure and vascular dysfunction.

OR-1855 is an active Levosimendan metabolite, has effect on human myometrial contractility.

FR-188582 is a highly selective cyclooxygenase (COX)-2 inhibitor [IC50: 17 nM].

Bayer-18 is an inhibitor of TYK2. It inhibits the viability of anaplastic large cell lymphoma cells, including K299, SR786, Mac1, and Mac2a, with an IC50 ranging from 2-3 µM. Additionally, Bayer-18 induces apoptosis in K299 and SR786 cells.

PROTAC SMARCA2 degrader-18 (Example144) is a PROTAC SMARCA2 degrader with potential for researching non-small cell lung cancer (NSCLC).

FGFR1 inhibitor-18 (compound 16) is a potent inhibitor of FGFR1 with an IC50 of 1.31 nM. It effectively occupies the ATP binding site of the target FGFR1.

FR-181157, a novel prostaglandin (PG) mimetic, shows high potency and agonist efficacy at the IP receptor and has good bioavailability.

FR-181877, a nonprostanoid PGI2 agonist, inhibits ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.

FR-182024 is a novel cephem derivative, it has potent anti-Helicobacter pylori activity.

FR-186054 is a new, potent inhibitor of acyl-CoA:cholesterol O-acyltransferase (ACAT) and has oral activity. Compared to other ACAT inhibitors, this compound displayed excellent in vitro efficacy, irrespective of dosing method, indicating superior charact

R-18893, a RNA-directed DNA polymerase inhibitor, is used potentially for the treatment of HIV-1 infection.

SSR-182289A (Free) is a thrombin inhibitor.

FR-182980 is a bio-active chemical. Detailed information has not been published.

SR-18292 is an inhibitor of PPAR gamma coactivator-1α (PGC-1α), which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

KRAS inhibitor-18 (compound 3-10) is a potent inhibitor of KRAS G12C (IC50: 4.74 μM) and exhibited p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50s of 66.4 μM and 11.1 μM, respectively. KRAS inhibitor-18 has potential for pancreatic, colorectal, and lung cancer studies.

BRD4 Inhibitor-18 is a potent BRD4 inhibitor (IC50: 110 nM) with a hydrophobic acetylcyclopentane side chain. BRD4 Inhibitor-18 significantly reduces the proliferation of MV-4-11 cells with high BRD4 levels, inhibits G0/G1 cycle activity, and promotes apoptosis. The inhibition of G0/G1 cycle activity and apoptosis were also observed.

HIV-1 inhibitor-18 is a potent inhibitor of the HIV-1 capsid that acts against the HIV-1 NL4-3 strain (EC50: 5.14 μM) and exhibits some cytotoxicity (MT-4CC50>9.51).

Water-18O is a useful organic compound for research related to life sciences and the catalog number is T64656.

THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.

PROTAC SMARCA2/4-degrader-18 (Compound I-348) is a PROTAC degrader targeting the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells with a DC50 value of less than 100 nM and similarly degrades SMARCA4 in MV411 cells, also with a DC50 of less than 100 nM.

RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.

SSR180711 hydrochloride (SSR-180711A HCl) is a selective Alpha7 nicotinic acetylcholine partial agonist for the study of neurodegenerative and cognitive disorders.